Skip to main content
. 2017 Jan 5;130(1):23–31. doi: 10.4103/0366-6999.196569

Table 1.

Demographics of kidney transplant recipients enrolled in this study

Patient number Gender Age (years) Height (cm) Body weight (kg) AHA Surgery Donor type IST Diagnosis (months PT) Stenosis (%) CTA after stent
1 Male 29 174 72 Yes Single Deceased FK + MMF + prednisone 6 90 Yes
2 Male 35 166 52 Yes Single Deceased FK + MMF + prednisone 4 90 Yes
3 Female 35 164 48 Yes Single Deceased FK + MMF + prednisone 5 90 Yes
4 Male 50 170 58 Yes CPKT Deceased CsA + MMF + prednisone 7 85 Yes
5 Female 31 163 54 Yes Single Deceased FK + MMF + prednisone 11 70 Yes
6 Male 40 165 50 Yes Single Deceased FK + MMF + prednisone 4 70 Yes
7 Male 35 176 75 Yes Single Deceased FK + MMF + prednisone 2 84 No
8 Male 32 170 68 Yes Single Deceased CsA + MMF + prednisone 3 80 No
9 Male 47 170 72 Yes Single Deceased CsA + MMF + prednisone 3 80 No
10 Male 25 173 68 Yes Single Living related FK + MMF + prednisone 1 75 No
11 Female 16 160 45 Yes Single Living related FK + MMF + prednisone 9 70 No
12 Male 27 170 60 Yes Single Deceased FK + MMF + prednisone 4 70 No
13 Male 29 174 72 No Single Deceased FK + MMF + prednisone 3 Control
14 Male 42 172 80 No Single Deceased FK + MMF + prednisone 24 Control
15 Male 38 170 56 No Autotransplant Deceased No 7 Control
16 Male 39 172 62 No Single Deceased FK + MMF + prednisone 13 Control
17 Female 36 168 53 No Single Living related CsA + EC−MPS + prednisone 8 Control
18 Male 40 165 50 No Single Deceased FK + MMF + prednisone 9 Control

AHA: Antihypertensive agent; CPKT: Combined pancreas–kidney transplantation; IST: Immunosuppressive therapy; FK: FK506; CsA: Cyclosporine A; MMF: Mycophenolate mofetil; EC–MPS: Enteric–coated mycophenolate sodium; PT: Posttransplant; CTA: Computed tomography angiography.